Cargando…

Acute myeloid leukemia in an 86-year-old man with AML1/ETO treated with Homoharringtonine and Arsenic Trioxide: A case report

RATIONALE: Acute myeloid leukemia (AML) is a malignantly clonal and highly heterogeneous disease. Although the treatment of AML has brought promising outcomes for younger patients, prognosis of the elderly remains dismal. Innovative regimens are increasingly necessary to be investigated. PATIENT CON...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Zhipeng, Chen, Meiling, Huang, Yiping, Chen, Lili, Wang, Bixin, Wang, Huixian, Yang, Mengting, Xiao, Xueting, Lu, Yanhong, Chen, Jiaying, Wu, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456030/ https://www.ncbi.nlm.nih.gov/pubmed/30921216 http://dx.doi.org/10.1097/MD.0000000000014998

Ejemplares similares

MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report
por: He, Zhipeng, et al.
Publicado: (2018)

Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms
por: Tan, Ming, et al.
Publicado: (2019)

The Metabolic Signature of AML Cells Treated With Homoharringtonine
por: Zhang, Yulong, et al.
Publicado: (2022)

Correction to: Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms
por: Tan, Ming, et al.
Publicado: (2019)

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein
por: Cao, Jiang, et al.
Publicado: (2016)

Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML
por: Mu, Guangfu, et al.
Publicado: (2020)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
por: Thiel, V N, et al.
Publicado: (2017)

P564: HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML
por: Luo, Xiao-Hua, et al.
Publicado: (2023)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome
por: Burnett, Alan K, et al.
Publicado: (2011)

Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia
por: Dou, Liping, et al.
Publicado: (2019)

A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis
por: Sun, Xiao-Jian, et al.
Publicado: (2013)

Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute Myelogenous Leukemia
por: Cho, Eun Kyung, et al.
Publicado: (2003)

TAF1 plays a critical role in AML1-ETO driven leukemogenesis
por: Xu, Ye, et al.
Publicado: (2019)

A Predictor Combining Clinical and Genetic Factors for AML1-ETO Leukemia Patients
por: Yang, Min, et al.
Publicado: (2022)

AML1-ETO-Related Fusion Circular RNAs Contribute to the Proliferation of Leukemia Cells
por: Wang, Ying, et al.
Publicado: (2022)

Minimal residual disease monitoring via AML1-ETO breakpoint tracing in childhood acute myeloid leukemia
por: Chen, Xiaoyan, et al.
Publicado: (2021)

AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
por: Rejeski, Kai, et al.
Publicado: (2021)

Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study
por: Li, Jing, et al.
Publicado: (2023)

Genome-wide co-occupancy of AML1-ETO and N-CoR defines the t(8;21) AML signature in leukemic cells
por: Trombly, Daniel J, et al.
Publicado: (2015)

A direct comparison between AML1-ETO and ETO2-GLIS2 leukemia fusion proteins reveals context-dependent binding and regulation of target genes and opposite functions in cell differentiation
por: Zhang, Yi-Fan, et al.
Publicado: (2022)

A novel epigenetic AML1‐ETO/THAP10/miR‐383 mini‐circuitry contributes to t(8;21) leukaemogenesis
por: Li, Yonghui, et al.
Publicado: (2017)

Modulation of Cellular Response to Arsenic Trioxide Toxicity by Resveratrol
por: Mondal, Bodhisattwa, et al.
Publicado: (2018)

FACSorting help to analyze a rare case of acute myeloid leukemia with concurrent AML1‐ETO and PML‐RARA
por: Chen, Man, et al.
Publicado: (2021)

MicroRNA let-7b downregulates AML1-ETO oncogene expression in t(8;21) AML by targeting its 3′UTR
por: Johnson, Daniel T., et al.
Publicado: (2021)

Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment
por: Chen, Baowei, et al.
Publicado: (2013)

Evidences of Protective Potentials of Microdoses of Ultra-High Diluted Arsenic Trioxide in Mice Receiving Repeated Injections of Arsenic Trioxide
por: Banerjee, Pathikrit, et al.
Publicado: (2011)

AML1-ETO Inhibits Maturation of Multiple Lymphohematopoietic Lineages and Induces Myeloblast Transformation in Synergy with ICSBP Deficiency
por: Schwieger, Maike, et al.
Publicado: (2002)

AML1/ETO sensitizes via TRAIL acute myeloid leukemia cells to the pro-apoptotic effects of hypoxia
por: Barbetti, V, et al.
Publicado: (2013)

Amyloid precursor protein has clinical and prognostic significance in AML1-ETO-positive acute myeloid leukemia
por: Yu, Guopan, et al.
Publicado: (2018)

KDM4B promotes acute myeloid leukemia associated with AML1‐ETO by regulating chromatin accessibility
por: Ueda, Takeshi, et al.
Publicado: (2021)

ABL1 kinase as a tumor suppressor in AML1-ETO and NUP98-PMX1 leukemias
por: Golovine, Konstantin, et al.
Publicado: (2023)

The antitumor effect of arsenic trioxide on hepatocellular carcinoma is enhanced by andrographolide
por: Duan, Xuhua, et al.
Publicado: (2017)

In silico mechanisms of arsenic trioxide-induced cardiotoxicity
por: Li, Yacong, et al.
Publicado: (2022)

Arsenic trioxide as an inducer of immunogenic cell death
por: Kepp, Oliver, et al.
Publicado: (2023)

Immunological consequences of arsenic trioxide-induced necrosis
por: Gavali, Shubhangi, et al.
Publicado: (2023)

Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells
por: Yang, C-H, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_b0p7gl5t20jre1d691jkiele99